Physician profile
William Gardner Rowell
NPI 1538109442
$816.69
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $244 · 2021: $31.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $175.81 | 2019-2020 | |
| Janssen Biotech, INC. | $169.55 | 2019-2020 | |
| Abbvie INC. | $142.25 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.98 | 2019 | |
| Ucb, INC. | $62.43 | 2019-2020 | |
| Pfizer INC. | $57.52 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $37.29 | 2019-2020 | |
| Concordia Pharmaceuticals INC. | $22.47 | 2019 | |
| Shire North American Group INC | $13.57 | 2019 | |
| Braintree Laboratories, INC. | $13.41 | 2020 | |
| Medtronic USA, INC. | $13.38 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.73 | 2020 | |
| Redhill Biopharma INC. | $11.30 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Rowell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.